BUSINESS● LOWSep 24 · Sep 24, 2026, 5:17 PM
Ligand, AvenCell ink financing deal worth up to $47M for CAR-T therapies
Seeking Alpha Tech · global
Ligand and AvenCell have finalized a financing agreement valued at up to $47 million for the development of CAR-T therapies. This deal supports research and development in the biotechnology and pharmaceutical sectors.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS38m agoReal estate stocks trade mixed as earnings releases pick paceSeeking Alpha TechBUSINESS46m agoNDPHC bids to end 15-year blackout in Kaduna community with substation projectVanguard Nigeria